These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 25064699)

  • 1. Benefit-risk assessment of orlistat in the treatment of obesity.
    Sumithran P; Proietto J
    Drug Saf; 2014 Aug; 37(8):597-608. PubMed ID: 25064699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orlistat: its current status as an anti-obesity drug.
    Ballinger A; Peikin SR
    Eur J Pharmacol; 2002 Apr; 440(2-3):109-17. PubMed ID: 12007529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
    Sjöström L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar HP; Krempf M
    Lancet; 1998 Jul; 352(9123):167-72. PubMed ID: 9683204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.
    Finer N; James WP; Kopelman PG; Lean ME; Williams G
    Int J Obes Relat Metab Disord; 2000 Mar; 24(3):306-13. PubMed ID: 10757623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity.
    Krempf M; Louvet JP; Allanic H; Miloradovich T; Joubert JM; Attali JR
    Int J Obes Relat Metab Disord; 2003 May; 27(5):591-7. PubMed ID: 12704403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet.
    Derosa G; Mugellini A; Ciccarelli L; Fogari R
    Clin Ther; 2003 Apr; 25(4):1107-22. PubMed ID: 12809960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
    Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orlistat: selective inhibition of caloric absorption can affect long-term body weight.
    Hauptman J
    Endocrine; 2000 Oct; 13(2):201-6. PubMed ID: 11186221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial.
    Bloch KV; Salles GF; Muxfeldt ES; Da Rocha Nogueira A
    J Hypertens; 2003 Nov; 21(11):2159-65. PubMed ID: 14597860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on orlistat in the management of patients with obesity.
    Curran MP; Scott LJ
    Treat Endocrinol; 2005; 4(2):127-9. PubMed ID: 15783249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.
    Derosa G; Maffioli P; Ferrari I; D'Angelo A; Fogari E; Palumbo I; Randazzo S; Cicero AF
    Fundam Clin Pharmacol; 2011 Oct; 25(5):642-51. PubMed ID: 21077943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Maffioli P
    J Clin Pharm Ther; 2012 Apr; 37(2):187-95. PubMed ID: 21812797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients].
    Sjostrom L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar H; Krempf M;
    Ter Arkh; 2000; 72(8):50-4. PubMed ID: 11019429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight management and current options in pharmacotherapy: orlistat and sibutramine.
    Leung WY; Thomas GN; Chan JC; Tomlinson B
    Clin Ther; 2003 Jan; 25(1):58-80. PubMed ID: 12637112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orlistat in the treatment of obesity.
    Hollander P
    Prim Care; 2003 Jun; 30(2):427-40. PubMed ID: 14567157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orlistat, a new lipase inhibitor for the management of obesity.
    Heck AM; Yanovski JA; Calis KA
    Pharmacotherapy; 2000 Mar; 20(3):270-9. PubMed ID: 10730683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E; Kolanowski J; Scheen A; Van Gaal L;
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of short-term (21-day) orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents.
    Zhi J; Moore R; Kanitra L
    J Am Coll Nutr; 2003 Oct; 22(5):357-62. PubMed ID: 14559927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orlistat.
    Wong NN; Cheng-Lai A
    Heart Dis; 2000; 2(2):174-81. PubMed ID: 11728255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.